GSK: Blenrep Approved in China for Treatment of 2L+ Relapsed/refractory Multiple Myeloma
April 21, 2026
April 21, 2026
LONDON, England, April 21 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on April 20, 2026:
* * *
Blenrep (belantamab mafodotin) approved in China for treatment of 2L+ relapsed/refractory multiple myeloma
* Blenrep combination showed a 42% reduction in risk of death and nearly tripled median progression-free survival versus a daratumumab-based triplet/1,2
* As the only anti-BCMA approved in 2L+ . . .
* * *
Blenrep (belantamab mafodotin) approved in China for treatment of 2L+ relapsed/refractory multiple myeloma
* Blenrep combination showed a 42% reduction in risk of death and nearly tripled median progression-free survival versus a daratumumab-based triplet/1,2
* As the only anti-BCMA approved in 2L+ . . .